HARMONY BIOSCIENCES

Q2 2026

Financial Results and Business Update

August 4, 2026

NASDAQ LISTED HRMY

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, our planned and ongoing clinical trials and expected timing of data readouts, anticipated regulatory milestones, our future results of operations and financial position, business strategy, products, prospective products, product approvals, and the plans and objectives of management for future operations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including EPX-100, Pitolisant GR and BP-205; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche ("Bioprojet"); the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions, including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

TWO DEFINING STORIES THIS QUARTER

GROWING

RECORD COMMERCIAL QUARTER

$261.3M

- Record quarterly net product revenue for WAKIX
- +30% vs. prior year; 40% CAGR over past 5 years
- +450 Net Patient Adds, 8,950 Average Patients

ADVANCING

BEST-IN-CLASS OX2R POTENTIAL

BP-205

- Encouraging single ascending dose (SAD) data; potential for once-daily dosing and favorable safety/tolerability profile
- Most potent of OX2R agonists currently in the clinic
- Investing in robust Phase 2 development program toward multiple CNS Indications

Value Inflection: On Track For >$1B Net Revenue in 2026 & Multiple BP-205 Data Catalysts Ahead

HARMONY BIOSCIENCES

EXECUTING AGAINST FOUR VALUE CREATION PRIORITIES

GROWING

GROW THE WAKIX® FRANCHISE

Continued WAKIX growth in an evolving market

On track to achieve >$1B full year net revenue

ADVANCING

ADVANCE BP-205 AND THE NEXT WAVE OF INNOVATION

Led by BP-205, a potentially best-in-class OX2R agonist

5 Phase 3 registrational trials in 5 distinct rare CNS indications

TRANSACTING

EMPHASIS ON BUSINESS DEVELOPMENT

Deploying strong balance sheet capacity with urgency and conviction to pursue strategic growth opportunities

PROTECTING

PROTECT THE PITOLISANT FRANCHISE

Exclusivity into 2030s, supported by multi-layered intellectual property

WAKIX® Differentiation and Strong Execution Drive Performance



DIFFERENTIATED PRODUCT

EXPANDED TEAM

BROAD PAYER ACCESS

- **A record $261M in net sales in 2Q26**
- **Up 30% percent year over year in year 7 on market**
- **+450 net patient adds, 8,950 average patients**

KEY TAKEAWAY

Historic Growth Rate Continued in 2Q 26

Growth Opportunity Across the Narcolepsy Market

People Living With Narcolepsy in the U.S.[1]



LARGE MARKET OPPORTUNITY

- ~170K total narcolepsy patients
- <50% diagnosed patients
- ~20% brand penetration in polypharmacy market

1. https://narcolepsynetwork.org/ accessed Feb 2024

KEY TAKEAWAY

Significant Growth Opportunity Remains for WAKIX and Next-Gen Pitolisant Formulations

Reiterating 2026 Net Revenue Guidance

WAKIX Net Revenue Growth 2020–2025



$1.00B-$1.04B

2026 NET REVENUE GUIDANCE

Wakix pitolisant tablets

On Track to Achieve $1B+ in Net Sales

HARMONY BIOSCIENCES

Advancing BP-205 and a Catalyst-Rich Pipeline for Long-Term Growth

PRODUCT	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY FILING
BP-205 (Orexin-2 Receptor Agonist)	Multiple CNS Indications					
Pitolisant	Pitolisant Gastro-Resistant (GR) in Narcolepsy					
	Prader-Willi Syndrome (PWS)					
	Pitolisant High-Dose (HD) in Narcolepsy					
	Pitolisant High-Dose (HD) in Idiopathic Hypersomnia					
	Pitolisant Amorphous Form					
CBS105^	Treatment-Resistant Narcolepsy					
EPX-100 (Clemizole Hydrochloride)	Dravet Syndrome (DS)					
	Lennox-Gastaut Syndrome (LGS)					
CBS104^	Refractory Epilepsy					



^Research collaboration with CiRC Biosciences.

Innovative Late-Stage Pipeline With Multiple Catalysts 2026–2028

BP-205: Most Potent OX2R Agonist in Clinical Development

Select DMPK parameters	HRMY/BP[1] BP-205	Takeda[2] TAK-861	Alkermes[3] 2680	Centessa/Lilly[4] ORX750	Eisai[5] E2086
Potency (hOX2R, EC50)	**0.015 nM**	2.5 nM	Not reported	0.11 nM	2.3 nM
Selectivity for hOX2R vs hOX1R	**> 600x**	3000x	Not reported	9800x	> 2000x
Dosing regimen	**Potential for once-daily oral dosing**	Twice a day dosing	QD/split-dose	QD/split-dose	Once a day dosing in Phase 1b

Potential Best-in-Class Orexin 2 Receptor Agonist

- Novel Chemical Scaffolding
- Most Potent OX2R Agonist in Clinical Development
- Excellent Selectivity

(In Vitro Pharmacology Data, vs. Selected OX2R agonists)

1. Sleep 2025; 2. Kimura et al., World Sleep 2023, abstract; 3. Clinicaltrials.gov; 4. Lack et al., World Sleep 2023, abstract; 5. Hatanaka et al., ACNP 2022, poster

BP-205: Single Ascending Dose (SAD) Phase 1 Study in Healthy Volunteers



RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, HEALTHY PARTICIPANTS

Males, women of childbearing potential and post-menopausal females

DOSES EVALUATED

BP-205 0.2mg to 6.0mg

9 DIFFERENT COHORTS OF 8 PARTICIPANTS

Receive single doses of either BP-205 (n=6) or placebo (n=2) under fasting conditions

A TOTAL OF 72 HEALTHY VOLUNTEERS

56 males and 16 females participated in the study

HARMONY BIOSCIENCES

BP-205: Single Ascending Dose (SAD) Phase 1 Study Data Highlights

ENCOURAGING DATA FOLLOWING SINGLE ORAL DOSES OF BP-205 FROM 0.2 TO 6.0 MG:

- **Rapid absorption and a short T_{max} in the range of 30 to 75 minutes**
  - Potential to observe rapid efficacy
- **Mean $T_{1/2}$ of approximately 25h across dose groups**
  - Supports once-a-day dosing potential for durable efficacy throughout the day and into the early evening
- **Dose proportional exposure in C_{max} and AUC**
  - Predictable systemic exposure across dose ranges tested
- **No age or gender differences on PK parameters**
  - Supports no dose adjustment for elderly or females
- **Generally safe and well tolerated**
  - No serious or severe TEAEs
  - No cardiovascular, hepatic or visual abnormalities
  - The most common AEs were headache, fatigue and diarrhea in
  - ~ 10%, 4% and 3% of the participants, respectively

BP-205 Development Plan – Next Steps

BP-205 MAD DATA IN HEALTHY VOLUNTEERS EXPECTED IN Q4

BP-205 IND OPEN IN US

INITIATING PHASE 1B STUDY IN SLEEP-DEPRIVED HEALTHY VOLUNTEERS IN Q3

Data expected early 2027

INITIATING PHASE 2 TRIALS FOR BP-205 IN MULTIPLE CNS INDICATIONS IN MID-2027

Next-Generation Pitolisant Programs

PITOLISANT GR – NDA ACCEPTED FOR FULL REVIEW
PDUFA date anticipated April 1, 2027

PITOLISANT HD – ONGOING PHASE 3 REGISTRATIONAL STUDIES IN NARCOLEPSY AND IH
TLD expected in 2027; Anticipated PDUFA in 2028

UTILITY PATENTS FILED FOR BOTH GR AND HD
Potential to extend the pitolisant franchise into the 2040s

PITOLISANT PHASE 3 STUDY IN PWS: RECRUITMENT ONGOING
TLD expected in mid-2027; Anticipated PDUFA in 2028

AMORPHOUS FORM OF PITOLISANT
- Issued patents until 2042
- Current efforts focused on formulation optimization and new modes of delivery; Phase 1 PK study ongoing

EPX-100: One of Most Advanced 5-HT2 (Serotonin) Agonist Programs in DEEs

ESTABLISHED 5-HT2 (SEROTONIN) AGONIST MECHANISM OF ACTION

ONGOING PHASE 3 TRIALS IN LENNOX-GASTAUT SYNDROME & DRAVET SYNDROME

Topline data anticipated 1H 2027

SAFETY: POTENTIAL TO OFFER A UNIQUE RISK/BENEFIT PROPOSITION

No additional laboratory or special safety monitoring

BID DOSING REGIMEN

Convenient for patients and caregivers

Emphasis on Business Development

KEY CRITERIA

- Revenues in 2028-2032
- Assets in Phase 3, In-Registration, or On-Market

LEVERAGE CORE COMPETENCIES

THERAPEUTIC AREAS OF INTEREST

- Sleep/Wake
- Epilepsy
- Rare/Orphan CNS
- Broader CNS indications

AGNOSTIC TO DEAL TYPE

- M&A, licensing, etc.

STRONG BALANCE SHEET WITH ~ $963M IN CASH

Protect the Pitolisant Franchise

STRONG IP PROTECTS WAKIX TO MARCH 2030, INCLUSIVE OF PEDIATRIC EXCLUSIVITY

Multi-layered IP estate – formulation, methods of use, next-gen applications

UTILITY PATENTS FILED FOR NEXT-GEN PITOLISANT FORMULATIONS

Potential protection into the 2040s

SETTLEMENTS WITH 6 OF 7 ANDA FILERS

ANDA CASE: DEFENDING POLYMORPH ‘197 AND METHOD OF USE ‘947 PATENTS

On HRMY’s request, judge has called for closing arguments on October 22, 2026

AMORPHOUS ‘920 PATENT INFRINGMENT

Harmony and Novitium filed patent infringement lawsuit against AET US and Sandoz alleging infringement of a patent covering amorphous form of pitolisant hydrochloride

Financial Summary Q2 2026

Totals may not foot due to rounding	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	% Change	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025	% Change
Net Product Revenue	**$261.3**	**$200.5**	**30%**	**$476.7**	**$385.2**	**24%**
Cost of Product Sold	63.2	38.2	65%	107.7	70.2	53%
Total Operating Expenses	**$108.8**	**$114.2**	**-5%**	**$242.5**	**$210.7**	**15%**
R&D Expense	46.6	50.2	-7%	116.0	84.7	37%
Sales & Marketing Expense	34.1	30.1	13%	65.8	60.8	8%
G&A Expense	28.1	33.9	-17%	60.6	65.2	-7%
Net Income	**$75.4**	**$39.8**	**90%**	**$107.9**	**$85.3**	**27%**
Cash, cash equivalents & investments	**$962.5**	**$672.3**	**43%**			

(In millions, USD)

- Cost of Product Sold increase due to new royalties related to Novitium License Agreement signed in Q1
- R&D Expense:
  - Q2 lower primarily due to $15 million payment to CiRC in prior year quarter
  - YTD increase driven by $32 million of licensing payments in Q1, as well as continued investment in our pipeline
- Sales & Marketing Expenses increase primarily due to expansion of our field-based team

HARMONY BIOSCIENCES

Financial Summary Q2 2026

Net Product Revenue



Diluted Earnings per Share



Cash, Cash Equivalents & Investments



(In millions, USD)

- Record sales in Q2 of $261 million representing 30% growth
- Continued strong underlying demand for WAKIX®
- Strong cash generation of $92 million in Q2
- Continued profitability to fund strategic business development and investment in our pipeline

HARMONY BIOSCIENCES

EXECUTING AGAINST FOUR VALUE CREATION PRIORITIES

GROWING

GROW THE WAKIX® FRANCHISE

Continued WAKIX growth in an evolving market

On track to achieve >$1B full year net revenue

ADVANCING

ADVANCE BP-205 AND THE NEXT WAVE OF INNOVATION

Led by BP-205, a potentially best-in-class OX2R agonist

5 Phase 3 registrational trials in 5 distinct rare CNS indications

TRANSACTING

EMPHASIS ON BUSINESS DEVELOPMENT

Strong balance sheet with capacity and conviction to pursue strategic growth opportunities

PROTECTING

PROTECT THE PITOLISANT FRANCHISE

Exclusivity into 2030s, supported by multi-layered intellectual property

THANK YOU

HARMONY BIOSCIENCES

company/harmonybiosciences/

@harmonybio

harmony_biosciences

NASDAQ LISTED HRMY

www.harmonybiosciences.com